Welcome to our dedicated page for COSCIENS BIOPHARMA news (Ticker: CSCIF), a resource for investors and traders seeking the latest updates and insights on COSCIENS BIOPHARMA stock.
COSCIENS Biopharma Inc. reports developments for a life science company focused on natural, plant-based active ingredients, with additional disclosures covering pharmaceutical therapies, diagnostic products, and related corporate actions. Company news includes operating and financial results, restructuring and cost-management updates, strategic decisions affecting subsidiaries, and commercialization matters for Macrilen, an oral diagnostic test for adult growth hormone deficiency.
Recurring updates also cover public-company status matters, including the company’s voluntary Nasdaq delisting, plans involving U.S. reporting obligations, shareholder meeting materials, capital-structure proposals, and responses to market activity in its common shares.
COSCIENS (FINRA: CSCIF, TSX: CSCI) announced it will cease funding its German subsidiaries Aeterna Zentaris GmbH and Zentaris IVF GmbH, prompting an expected structured insolvency process and anticipated surrender of rights to Macrilen® (macimorelin). The company cited disappointing Phase 3 DETECT results and a Type C FDA meeting as a setback to pediatric expansion plans.
The company said it will significantly reduce operating expenses and refocus on its active ingredients business, while evaluating other strategic options including sales, licenses, and U.S. entry alternatives.
COSCIENS (TSX: CSCI; FINRA: CSCIF) announced that subsidiary Aeterna Zentaris GmbH signed an exclusive 10-year distribution agreement with Wuzhou Drug International for Macrilen (macimorelin) in Hong Kong, Macao, Singapore, and Guangdong and Hainan provinces.
The deal assigns Wuzhou responsibility for registration, importation and commercialization and leverages the "Hong Kong and Macao Medicine and Equipment Connect" policy for expedited access in the Greater Bay Area. The agreement includes a minimum initial order of approximately €800,000.